BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 19843881)

  • 1. How I treat hairy cell leukemia.
    Grever MR
    Blood; 2010 Jan; 115(1):21-8. PubMed ID: 19843881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern strategies for hairy cell leukemia.
    Grever MR; Lozanski G
    J Clin Oncol; 2011 Feb; 29(5):583-90. PubMed ID: 21220590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
    Shao H; Calvo KR; Grönborg M; Tembhare PR; Kreitman RJ; Stetler-Stevenson M; Yuan CM
    Leuk Res; 2013 Apr; 37(4):401-409. PubMed ID: 23347903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hairy cell leukemia].
    Maitre E; Wiber M; Cornet E; Troussard X
    Presse Med; 2019; 48(7-8 Pt 1):842-849. PubMed ID: 31447330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic variations in hairy cell leukemia.
    Chen YH; Tallman MS; Goolsby C; Peterson L
    Am J Clin Pathol; 2006 Feb; 125(2):251-9. PubMed ID: 16393677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of hairy cell leukemia by flow cytometry.
    Stetler-Stevenson M; Tembhare PR
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():11-3. PubMed ID: 21504292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recurrent somatic mutation in hairy cell leukemia].
    Sári E; Nagy Z; Demeter J
    Orv Hetil; 2013 Jan; 154(4):123-7. PubMed ID: 23335721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
    Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
    Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical hairy cell leukemia.
    Wu ML; Kwaan HC; Goolsby CL
    Arch Pathol Lab Med; 2000 Nov; 124(11):1710-3. PubMed ID: 11079033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?].
    Troussard X; Maitre E; Paillassa J
    Bull Cancer; 2021; 108(7-8):771-778. PubMed ID: 34023063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens.
    Noel P
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():62-4. PubMed ID: 21463123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.
    Cornet E; Delmer A; Feugier P; Garnache-Ottou F; Ghez D; Leblond V; Levy V; Maloisel F; Re D; Zini JM; Troussard X;
    Ann Hematol; 2014 Dec; 93(12):1977-83. PubMed ID: 24994538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hairy cell leukemia: an update.
    Goodman GR; Bethel KJ; Saven A
    Curr Opin Hematol; 2003 Jul; 10(4):258-66. PubMed ID: 12799530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
    Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hairy-cell leukemia].
    Damasio EE; Lamparelli T; Chimirri F
    Recenti Prog Med; 1993 May; 84(5):369-88. PubMed ID: 8511396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hairy cell leukemia.
    Chihara D; Kreitman RJ
    Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
    Kreitman RJ; Arons E
    Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease, its detection and significance in hairy-cell leukemia.
    Zák P; Chrobák L; Dĕdic K
    Acta Medica (Hradec Kralove); 1999; 42(3):85-8. PubMed ID: 10677893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.